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Abstract
Apart from its role during labor and lactation, oxytocin is involved in several other functions. Interestingly, oxytocin- and
oxytocin receptor-deficient mice develop late-onset obesity with normal food intake, suggesting that the hormone might
exert a series of beneficial metabolic effects. This was recently confirmed by data showing that central oxytocin infusion
causes weight loss in diet-induced obese mice. The aim of the present study was to unravel the mechanisms underlying
such beneficial effects of oxytocin. Chronic central oxytocin infusion was carried out in high fat diet-induced obese rats. Its
impact on body weight, lipid metabolism and insulin sensitivity was determined. We observed a dose-dependent decrease
in body weight gain, increased adipose tissue lipolysis and fatty acid b-oxidation, as well as reduced glucose intolerance and
insulin resistance. The additional observation that plasma oxytocin levels increased upon central infusion suggested that
the hormone might affect adipose tissue metabolism by direct action. This was demonstrated using in vitro, ex vivo, as well
as in vivo experiments. With regard to its mechanism of action in adipose tissue, oxytocin increased the expression of
stearoyl-coenzyme A desaturase 1, as well as the tissue content of the phospholipid precursor, N-oleoyl-phosphatidyl-
ethanolamine, the biosynthetic precursor of the oleic acid-derived PPAR-alpha activator, oleoylethanolamide. Because
PPAR-alpha regulates fatty acid b-oxidation, we hypothesized that this transcription factor might mediate the oxytocin
effects. This was substantiated by the observation that, in contrast to its effects in wild-type mice, oxytocin infusion failed to
induce weight loss and fat oxidation in PPAR-alpha-deficient animals. Altogether, these results suggest that oxytocin
administration could represent a promising therapeutic approach for the treatment of human obesity and type 2 diabetes.
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Introduction
The neurohypophysial hormone, oxytocin (OT), is a nonapep-
tide synthesized both centrally and peripherally. Within the central
nervous system, the OT gene is expressed in neurons of the
hypothalamic paraventricular (PVN) and supraoptic nuclei. The
magnocellular OT neurons in these nuclei project to the
neurohypophysis and are the major source of systemically released
OT, whereas parvocellular OT neurons of the PVN project
centrally. OT is also synthesized peripherally in several organs,
including the ovary, testis, thymus, kidney, and heart [1]. To date,
a single OT receptor (OTR) has been cloned. It is expressed in
various tissues, including adipose tissue [1]. Consistent with its
wide distribution of production and binding sites, OT has been
implicated in several central and peripheral processes [1].
Amongst these, acute peripheral or central OT injections were
shown to decrease food intake in rats [2]. Interestingly, in patients
with the Prader-Willi syndrome, characterized by extreme
hyperphagia leading to morbid obesity, a reduced number of
OT neurons and a smaller volume of the PVN-containing OT-
expressing neurons were reported [3]. Recent evidence also
suggests that OT might be involved in the regulation of metabolic
homeostasis. Thus, it was demonstrated that mice deficient in
either OT or OTR developed late onset obesity despite normal food
intake [4,5]. Additionally, plasma OT levels were reported to be
decreased in diet-induced obese mice and increased in synapto-
tagmin-4 deficient mice that are protected against diet induced
obesity [6]. Finally, central OT infusion was shown to cause body
weight loss in diet-induced obese mice [6]. However, the
mechanisms underlying such beneficial effects of central OT
infusion on metabolic homeostasis have not been unraveled so far
and their understanding was therefore the first aim of the present
study. Our results revealed that central OT infusion causes weight
loss in diet-induced obese rats by increasing adipose tissue lipolysis
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and fatty acid b-oxidation via the production of oleoylethanola-
mide, a PPAR-alpha activator [7]. Our second aim was to
delineate the pathways involved in such central OT effects. It
should be recalled at this point that OT is one of the few hormones
known to induce its own synthesis, as well as central and
peripheral release [1]. This occurs in physiological situations,
such as lactation and labor, during which OT is synthesized
centrally and released into the bloodstream to act on its target
tissues, namely the mammary gland and the uterus [1]. Data in the
literature also indicate that OT exerts direct actions on human
multipotent adipose-derived stem (hMADS) cells, as well as in
isolated adipocytes, although the latter results depended on the
OT dose used [8,9]. Due to the above-mentioned considerations,
the possibility that centrally infused OT might influence adipose
tissue metabolism by direct peripheral action was tested and
demonstrated using three different experimental approaches.
Finally, we strengthened the hypothesis that OT might influence
body weight gain and adipose tissue metabolism via PPAR-alpha
by testing its effects in PPAR-alpha knockout mice.
Materials and Methods
Ethics statement
All procedures were performed in accordance with the
Institutional Ethical Committee of Animal Care in Geneva and
Cantonal Veterinary Office. The Institutional Ethical Committee
of Animal Care in Geneva and Cantonal Veterinary Office
approved this study through experimentation ID: 1034/3025/
2-R.
Animals
Male Wistar rats (300–325 g) were fed a 45% high fat diet
(HFD) (SsniffH EF R/M acc. D12451 (I) mod., ssniff Spezialdia¨ten
GmbH, Soest, Germany) for 7 weeks to induce obesity. PPAR-
alpha knockout [10] and wild-type mice received normal mice
chow.
Treatments
Centrally infused HFD-induced obese rats were intracerebro-
ventricularly (i.c.v.) infused with saline or OT (NeoMPSH,
Strasbourg, France) delivered continuously at doses of 1.6 nmol/d
or 16 nmol/d over 14 days using osmotic minipumps (AlzetH,
model 2001, Alza Corporation, Cupertino, CA), as previously
described [11]. These doses of OT were chosen on the basis of the
literature [2], as well as on preliminary acute experiments carried
out before starting this project. Peripherally infused lean and
HFD-induced obese rats received subcutaneous (s.c.) infusions of
saline or OT at 50 nmol/d for 14 days using osmotic minipumps.
Pair-fed controls were included when OT infusions reduced food
intake. PPAR-alpha knockout and wild-type mice were subcuta-
neously infused with saline or OT at 50 nmol/day for 3 days using
osmotic minipumps.
Feeding pattern parameters, respiratory exchange ratio
and locomotor activity
Analyzes were performed at the end of the 2 week central
infusion using the 12-cage LabMaster system (TSE Systems
GmbH, Berlin, Germany) of the Small Animal Phenotyping Core
Facility (CMU, University of Geneva, Geneva), under controlled
temperature (2261uC) and lighting (12 h light-dark cycle). The
LabMaster consists in a combination of highly sensitive feeding
and drinking sensors for automated online measurements. Before
recording, animals were allowed a 4-day acclimatization period in
training cages.
Plasma measurements
Plasma glucose was measured with the glucose oxidase method
(Glu, Roche Diagnostics GmbH, Rotkreuz, Switzerland). Plasma
nonesterified fatty acid (FFA), glycerol and triglyceride (TG) levels
were determined with commercial kits (NEFA C: Wako Chem-
icals, GmbH, Neuss, Germany; Glycerol: Free Glycerol Reagent,
Sigma, Switzerland and TG enzymatic PAP150: Biome´rieux,
Marcy l’Etoile, France). Plasma OT levels were determined with a
home-made ELISA [12]. Measurements were performed at the
end of the 14-day treatment periods.
Glucose tolerance tests
Glucose (1.5 g/kg body wt) was intraperitoneally administered
4 h after food removal. Blood glucose levels were measured from
tail blood samples collected at 0, 15, 30, 60, 90, and 120 min after
glucose injection.
Euglycemic-hyperinsulinemic clamps
Global glucose utilization rates were measured with euglycemic-
hyperinsulinemic clamps [13].
Body composition
When OT was delivered peripherally in rats, an EchoMRI-700
quantitative nuclear magnetic resonance analyzer (Echo Medical
Systems, Houston, TX) was used to measure total fat mass and
lean body mass at the beginning and the end of treatments (days 0
and 10).
Primer sequences
Primers were designed with PrimerExpress software (http://
phym.unige.ch/) (Table S1). Results were normalized to the
expression levels of ribosomal protein S29.
Endocannabinoids
Endocannabinoids were measured as previously described [14].
In vitro experiments
Murine 3T3-L1 fibroblasts [15] were cultured in Dulbecco’s
modified eagle medium (DMEM) with 4.5 g/l glucose supple-
mented with 10% heat-inactivated depleted calf serum at 37uC,
Figure 1. Central OT infusion causes body weight loss
independently from changes in food intake. The measurements
were performed over a 14-day experimental period (weeks 5 through 7
of a high fat diet): (A) Cumulative body weight changes; (B) cumulative
food intake; (C) food efficiency ((body weight gain/cumulative food
intake over the 2 week experimental period) x 100). Filled bars: i.c.v.
saline–infused controls; open bars: i.c.v. OT-infused rats (1.6 nmol/d).
Values are mean 6 SEM of 6 to 7 rats/group. *P,0.05 compared to
controls.
doi:10.1371/journal.pone.0025565.g001
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8% CO2. They were induced to differentiate into adipocytes at
two days post confluence as described in [16]. Differentiation was
assumed when over 90% of cells showed large lipid droplets in the
cytoplasm. After differentiation, 3T3-L1 adipocytes were incubat-
ed with saline and 5 mM OT during 24 h.
Lipolysis assay
Epididymal fat pads from lean Wistar rats were incubated at
37uC in the presence of Krebs-Ringer-Hepes buffer containing 2%
FA-free BSA and 0.1% glucose. After 4 h of incubation in the
presence of either saline or OT (10 nM), the amount of glycerol
and free fatty acid released in the medium were determined with
commercial kits (Glycerol: Free Glycerol Reagent, Sigma,
Switzerland; NEFA C: Wako Chemicals, GmbH, Neuss, Ger-
many).
Statistics
Results are expressed as means 6 SEM. For experiments
including two sets of data, comparisons were performed with
parametric (Student’s t test) and non-parametric (Mann-Whitney
test) tests when normality and equal variance failed. Experiments
with more than two groups were analyzed using ANOVA,
followed by the post-hoc Bonferroni test. Statistical significance
was established at *P,0.05, **P,0.01, ***P,0.005.
Results
OT infusion decreases body weight gain
To study the role of OT on metabolic homeostasis, rats were
fed a high fat diet (HFD, 45% fat) for 7 weeks to induce obesity.
During the last 2 weeks of diet-induced obesity, the animals
were intracerebroventricularly (i.c.v.) infused with either OT
(1.6 nmol/d) or saline using osmotic minipumps. Chronic i.c.v.
OT infusion lowered body weight gain, resulting in more than a
50% decrease in cumulative body weight gain compared with the
effect of saline (Figure 1A; P,0.05). This occurred without any
change in food intake (Figure 1B) or in meal patterns (Table S2),
therefore leading to a marked decrease in food efficiency (Figure
1C; P,0.05).
OT infusion stimulates lipid metabolism
To determine whether OT modulated peripheral metabolism,
we determined plasma glucose, insulin, leptin, free fatty acid
(FFA), glycerol and triglyceride (TG) levels. Of these parameters,
only glycerol and TG concentrations were affected by central OT
infusion, the former being increased, while the latter were reduced
(Table 1; P,0.05). To delineate the mechanisms responsible for
the decrease in TG levels, we analyzed the expression of enzymes
involved in lipid metabolism in adipose tissue. This is indeed an
important tissue for lipid metabolism, in which the OTR appears to
be expressed, as determined in primary and cultured adipocytes
[17,18,19]. We focused on epididymal white adipose tissue
(eWAT), as it is considered an intra-abdominal fat depot with
high metabolic relevance. Central OT infusion promoted an
increase in the eWAT mRNA expression of lipoprotein lipase (Lpl)
(Figure 2A; P,0.01) and fatty acid transporter (Fat, also known as
CD36) (Figure 2A; P,0.05), two enzymes responsible for the
uptake of circulating TG and fatty acids, respectively. It did not
modify the expression of enzymes involved in lipogenesis and TG
storage; for example, acetyl-coenzyme A carboxylase alpha (Acaca,
also known as ACC-alpha), fatty acid synthase (Fasn), and
diacylglycerol O-acyltransferase homolog 1 (Dgat1). However,
central OT infusion increased the mRNA levels of two enzymes
involved in lipolysis, namely patatin-like phospholipase domain
containing 2 (Pnpla2) (P,0.05) and hormone-sensitive lipase (HSL)
(P,0.01). The stimulatory effect of OT on HSL was also detected
at the protein level (Figure 2B; P,0.05).
Due to the increases in TG uptake and in lipolysis, we expected
enhanced intracellular availability of FFA in adipocytes, as well as
elevated circulating FFA levels in OT-infused rats compared to
controls. However, the plasma FFA concentrations were unaltered
by central OT infusion (Table 1). This suggested that FFA
utilization had increased. We therefore measured the mRNA
expression of enzymes involved in fatty acid b-oxidation. We
found that OT infusion increased the eWAT expression of acyl-
CoA oxidase 1 (Acox1) (Figure 2C; P,0.05), enoyl-CoA hydratase/
3-hydroxyacyl-CoA dehydrogenase (Ehhadh, also known as HD)
(P,0.05), medium chain acyl-CoA dehydrogenase (Acadm, also
known as MCAD) (P,0.05), and uncoupling protein 3 (Ucp3)
(P,0.05). However, we did not observe any change in the
expression of PPAR-alpha, a ligand-activated transcription factor
that regulates the expression of the genes encoding the above-
mentioned proteins.
To determine whether these results were specific for adipose
tissue, we evaluated the mRNA expression of most of these lipid
metabolism-related genes in skeletal muscles and in the liver. We
observed that central OT infusion did not modify the expression of
these genes in quadriceps and in the liver (Figure S1), a tissue in
which the OT receptor expression is suppressed by CpG island
methylation in the gene promoter region [20]. These results
suggest that the OT anti-obesity effects are primarily exerted at the
level of adipose tissue.
OT infusion increases oleoylethanolamide production in
adipose tissue
We then attempted to unravel the mechanisms responsible for
the OT-induced stimulatory effect on adipocyte fatty acid b-
oxidation. As shown in Figure 2D, central OT infusion promoted
a marked increase in the mRNA expression of stearoyl-coenzyme
A desaturase 1 (Scd1; Figure 2D; P,0.05). Scd1 converts the
saturated fatty acids, palmitic acid (16:0) and stearic acid (18:0)
into the monounsaturated fatty acids, palmitoleic acid (16:1) and
oleic acid (18:1), respectively. The resulting fatty acids can either
be incorporated into the cell membrane as phospholipids (PL) or
Table 1. Effects of i.c.v. oxytocin (1.6 nmol/d) infusion on
plasma glucose, insulin, leptin, FFA, glycerol, TG,
oleoylethanolamide (OEA), palmitoylethanolamide (PEA),
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) levels.
Saline-infused rats OT-infused rats
Glucose (mg/dl) 159.165.7 159.564.1
Insulin (ng/ml) 2.560.7 1.760.3
Leptin (ng/ml) 13.963.7 11.362.2
FFA (mmol/l) 0.8260.06 0.7060.06
Glycerol (mg/ml) 50.665.1 63.663.2 *
TG (mmol/l) 1.1160.09 0.8060.05 *
OEA (pmol/ml) 145613 178615
PEA(nmol/ml) 1.3460.16 1.6360.15
AEA (pmol/ml) 1862.9 1962.3
2-AG (pmol/ml) 78613 5364.9
Values are mean 6 SEM of 6–7 animals per group. * P,0.05 versus saline-
infused controls. P =NS for all other comparisons.
doi:10.1371/journal.pone.0025565.t001
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stored as TG [21]. Because we did not observe any changes in the
mRNA expression of enzymes involved in TG storage in the
eWAT of OT-infused animals (Figure 2A), we hypothesized that
OT might have increased palmitoleic and oleic acid synthesis and
their incorporation as PL into the cell membrane. We further
reasoned that oleic acid can be transferred from the sn-1 position
of phosphatidylcholine (PC) to the free amine of phosphatidyleth-
anolamine (PE) in order to form N-oleoyl-phosphatidylethanol-
amine (NOPE) [7]. Then, NOPE is cleaved by N-acyl-phospha-
tidylethanolamine phospholipase D (NAPE-PLD) to release
oleoylethanolamide (OEA), a member of the N-acylethanolamine
family. Therefore, we could infer changes in membrane PL
incorporation by measuring changes in OEA production in
adipose tissue. We found that, compared to saline infusion, chronic
i.c.v. OT administration increased the OEA content in eWAT
(Figure 2E; P,0.05). Of note, OT did not modify the eWAT
content of other related lipids, including the saturated analog
palmitoylethanolamide (PEA), derived from palmitic acid, or the
endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol
(2-AG), derived from arachidonic acid (data not shown), nor did it
alter hepatic (data not shown), or plasma levels of OEA or other
endocannabinoids (Table 1). Interestingly, OEA is an agonist of
PPAR-alpha that was demonstrated to bind to the PPAR-alpha
ligand-binding-domain (LBD), leading to the activation of PPAR-
Figure 2. Central OT infusion stimulates lipid metabolism. The following analyses were performed on epididymal white adipose tissue (eWAT)
of i.c.v. saline–infused controls (filled bars) and i.c.v. OT-infused rats (1.6 nmol/d; open bars): (A) mRNA expression of enzymes related to lipid
metabolism; (B) Western blot analysis of HSL standardized to actin expression; (C) mRNA expression of PPAR-alpha and PPAR-alpha target genes; (D)
Scd1 mRNA expression; (E) Oleoylethanolamide (OEA) content in eWAT. Values are mean6 SEM of 6 to 7 rats/group. *P,0.05, **P,0.01 compared to
controls.
doi:10.1371/journal.pone.0025565.g002
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alpha transcriptional activity [22]. Moreover, OEA has been shown
to stimulate lipolysis and fatty acid oxidation, effects resulting from
an OEA-induced activation of PPAR-alpha [23,24]. Thus, the
observation that OT increased OEA synthesis and PPAR-alpha
target gene expression suggests that although OT does not increase
PPAR-alpha expression, it stimulates its transcriptional activity by
increasing eWAT levels of the PPAR-alpha ligand, OEA.
Dose-dependency of the effect of OT infusion
Knowing that OEA is an agonist of PPAR-alpha [7], we
postulated that it may mediate the stimulatory effects of OT on
lipid oxidation in adipose tissue. To strengthen this hypothesis, we
first examined the dose-dependency of these effects. HFD-induced
obese rats were i.c.v. infused for 14 days with a ten-fold higher
dose of OT (16 nmol/d), using osmotic minipumps. As shown in
Figure 3B, central OT infusion at this dose promoted a decrease in
cumulative food intake compared to controls (P,0.05). Upon
studying meal patterns at the end of the 2 week central OT or
saline infusion, we observed a reduction in meal number (Table
S3, P,0.05), without any change in meal size or duration. The
satiety ratio (intermeal interval/meal size), an index of the satiety
time produced by each gram of food consumed, was higher in OT-
Figure 3. Dose-dependency of the effect of central OT infusion. After 14-day treatments (weeks 5 to 7 of high fat diet, 45% fat), the following
measurements were made in i.c.v. saline–infused controls (filled bars), i.c.v. OT-infused rats (16 nmol/d; open bars), and i.c.v. saline-infused pair-fed
(PF) controls (hatched bars): (A) Delta body weight gain; (B) cumulative food intake; (C) plasma leptin levels; (D) respiratory exchange ratio (VO2:
VCO2); (E) Scd1 mRNA expression; (F) OEA content in epididymal white adipose tissue (eWAT); and (G) mRNA expression of lipid metabolism-related
enzymes in eWAT. Values are mean 6 SEM of 6 to 7 animals/group. *P,0.05, **P,0.01, ***P,0.005, compared to controls.
doi:10.1371/journal.pone.0025565.g003
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than in saline-infused animals (Table S3, P,0.05). Locomotor
activity was unaltered by either the low (1.6 nmol/d) or the high
dose (16 nmol/d) of central OT infusion (data not shown).
To determine the metabolic effects elicited by OT independently
from changes in food intake, a saline-infused control group was pair-
fed (PF) to match the consumption of OT-treated animals. Body
weight gain (Figure 3A; P,0.005) as well as plasma leptin levels
(Figure 3C; P,0.05) of OT-infused rats were decreased compared to
the saline–infused and the PF control groups. The respiratory
exchange ratio (RER), measured by indirect calorimetry, was also
lower in OT- than in saline-infused animals (Figure 3D; P,0.05),
independently from changes in food intake (Figure 3D; P,0.01). This
indicated a lower rate of carbohydrate utilization and a higher rate of
lipid oxidation, suggesting that OT-infused rats used more lipids as
energy source than the two control groups. Of note, we observed that
energy expenditure was unaltered by central OT infusion (data not
shown). In addition, the high dose of OT stimulated Scd1 mRNA
expression and OEA eWAT content more markedly than the low
dose (5.6- and 2.0-fold versus 4.2- and 1.3-fold stimulations,
respectively). This further indicated that central OT action on lipid
metabolism in adipose tissue involved OEA synthesis via Scd1,
independent from changes in food intake (Figures 3E and F; P,0.05).
Consistent with the results found with the ten-fold lower dose, the
16 nmol/d OT infusion did not modify the eWAT mRNA
expression of PPAR-alpha, but resulted in food intake-independent
increases in the expression of the PPAR-alpha target genes Acox1 and
Ehhadh (Figure 3G; P,0.05). It also stimulated the expression of the
genes encoding the main lipolytic enzymes, Pnpla2 and HSL (P,0.05).
Central OT infusion increases OT synthesis and release
into the bloodstream
Knowing that OT itself can activate OT neurons, thereby
inducing its own synthesis, as well as central and peripheral
release, we next determined the impact of chronic i.c.v. OT
infusion on hypothalamic OT mRNA expression, as well as
circulating OT levels.
As shown by Figure 4, both doses of chronic i.c.v. OT infusion
increased hypothalamic OT mRNA expression, as well as plasma
OT levels. Moreover, while 1.6 nmol/d OT infusion led to a
3-fold increase in plasma OT levels (Figure 4B; P,0.05), the ten-
fold higher dose (16 nmol/d) resulted in a 15-fold increase in these
levels (Figure 4D; P,0.05). This occurred in the presence of
similar changes in OT mRNA expression in response to the two
doses, suggesting that OT dose-dependently affected its own
release, rather than synthesis.
Of note, we observed that the eWAT mRNA expression of OT
and OTR was unaltered by either the low (1.6 nmol/d) or the high
dose (16 nmol/d) of central OT infusion (Figure S2).
Altogether, these observations suggested that OT might
modulate lipid metabolism in adipose tissue by direct action.
OT affects peripheral lipid metabolism by direct
peripheral action
To test the hypothesis that OT could affect peripheral lipid
metabolism by direct peripheral action, we first assessed the effect
of OT on lipid metabolism in vitro using differentiated 3T3-L1
adipocytes, known to express the OTR upon differentiation [19].
As shown in Figure 5A, OT increased the mRNA expression of all
the lipid metabolism-related genes that were affected by in vivo
central OT infusion. This included a stimulatory effect of OT on
PPAR-alpha, which was not observed in WAT in vivo. Additionally,
using the same in vitro system, we observed that OEA induced the
mRNA expression of PPAR-alpha and of most of the PPAR-alpha
target genes (Figure S3).
We next examined the effect of OT on lipolysis in ex vivo
incubated epididymal fat pads from lean rats. As shown in Figure
5B, OT significantly increased glycerol release, suggesting
increased adipose tissue lipolysis. In addition and in keeping with
the results obtained in vivo, OT did not affect fatty acid release
(Figure 5C), suggesting increased fatty acid b-oxidation.
Finally, we determined whether chronic peripheral OT infusion
could affect lipid metabolism in vivo, in both lean and HFD-
induced obese rats. Lean rats were peripherally infused with OT
(50 nmol/d for 14 days, subcutaneous minipumps). At this dose,
OT administration decreased food intake and body weight gain
(Figures 5D and E; P,0.05). The impact of peripheral OT
infusion on body composition was also evaluated using an
EchoMRI-700 analyzer. We observed that OT promoted a
significant decrease in fat mass and a concomitant increase in the
percent lean body mass, independently from changes in food
intake (Figure 5F; P,0.05).
Similar results, but more marked, were obtained by peripherally
infusing OT in HFD-induced obese rats. Thus, when HFD-
induced obese rats were peripherally infused with OT (50 nmol/d
for 14 days, subcutaneous minipumps), the peptide decreased food
intake and caused a strong body weight loss (Figures 6A and B;
Figure 4. Central OT infusion induces hypothalamic OT
synthesis and release into the bloodstream. The following
parameters were measured at the end of 14-day treatments with two
doses of i.c.v. OT infusion: (A) Oxytocin expression (Oxt) in rat
hypothalamus; (B) plasma OT levels in saline–infused controls (filled
bars) and OT-infused rats (1.6 nmol/d, open bars). Values are mean 6
SEM of 6 to 7 rats/group. *P,0.05 compared to controls; (C) Oxytocin
expression (Oxt) in rat hypothalamus; (D) plasma OT levels in saline–
infused controls (filled bars), OT-infused rats (16 nmol/d, open bars) and
pair-fed (PF) controls (hatched bars). Values are mean 6 SEM of 6 to 7
rats/group. *P,0.05 compared to controls.
doi:10.1371/journal.pone.0025565.g004
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P,0.05). Such body weight loss was unrelated to the anorexigenic
effect of the hormone, as it was not observed in the PF control
group (Figure 6A). OT also promoted a significant decrease in fat
mass and a concomitant increase in percent lean body mass,
independently from changes in food intake (Figure 6C; P,0.05).
Accordingly, we observed that OT decreased the eWAT TG, but
did not change the FFA content (Figure S4). The OT-induced
decrease in adipose tissue glycerol levels suggests that this
metabolite is exported from the tissue into the bloodstream.
Importantly in view of the potential direct OT action on adipose
tissue, peripheral OT administration resulted in a 20-fold increase
in plasma OT levels (Figure 6D; P,0.05). This was accompanied
by increases in the eWAT content of OEA (Figure 6F, P,0.05), as
well as its phospholipid precursor, N-oleoyl-phosphatidylethanol-
amine (NOPE) (Figure 6E, P,0.05) that were not mediated by the
anorexigenic effect of OT.
PPAR-alpha mediates direct peripheral OT action on lipid
metabolism
Based on our observation that OT infusion dose-dependently
increased the adipose tissue content of the PPAR-alpha agonist,
OEA, we reasoned that OEA might mediate the effects of OT
through its action on PPAR-alpha transcriptional activity. To test
this hypothesis, we infused OT peripherally in PPAR-alpha
knockout (KO) and wild-type (WT) mice. As expected, the
peripheral OT infusion induced a significant reduction in body
weight gain in WT animals. However, it did not modify weight
gain in PPAR-alpha KO mice (Figure 7A; P,0.05). Accordingly,
the OT infusion promoted an increase in the mRNA expression of
PPAR-alpha target genes in WT mice (Acox1, Ehhadh, Acadm and
Ucp3), but had no effect in the PPAR-alpha knockout animals
(Figure 7B). Interestingly, Scd1 expression similarly increased in
both groups (Figure 7B, P,0.05), suggesting that the OT effect on
Scd1 was upstream PPAR-alpha activation.
Both central and peripheral OT infusion reduces insulin
resistance
In view of the observations that OT-deficient mice, known to
develop late-onset obesity, also exhibit decreased insulin sensitivity
and impaired glucose tolerance [4], we determined whether
chronic central OT infusion would affect these parameters in
HFD-induced obese rats. We therefore performed glucose
Figure 5. OT directly affects lipid metabolism. (A) Lipid metabolism-related enzyme expression in differentiated 3T3-L1 adipocytes (24 h saline
or 5 mM OT). Values are mean 6 SEM of three independent experiments. *P,0.05, **P,0.01 compared to controls. (B–C) Epididymal fat pads from
lean Wistar rats were incubated at 37uC in the presence of Krebs-Ringer-Hepes buffer containing 2% FA-free BSA and 0.1% glucose. After 4 h of
incubation in the presence of either saline or OT (10 nM), the amount of (B) glycerol and (C) free fatty acid released in the medium was measured.
Values are mean 6 SEM of three independent experiments. (D–F) Measurements performed over the 14-day s.c. saline or OT treatment in lean rats
fed a standard diet: (D) Cumulative body weight gain; (E) cumulative food intake; (F) changes in body composition between days 0 and 10 of
treatment. Saline–infused controls (black circles, filled bars), OT-infused rats (50 nmol/d; white diamonds, open bars), and saline-infused PF controls
(black triangles, hatched bars). Values are mean 6 SEM of 6 to 7 rats/group. *P,0.05.
doi:10.1371/journal.pone.0025565.g005
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tolerance tests (GTT) and euglycemic-hyperinsulinemic clamps in
i.c.v. saline- and OT-infused animals. Two GTTs were carried
out: the first one after 3 weeks of HFD, and the second one after 7
weeks of HFD, at the end of the 2-week saline or OT infusion. We
observed that, after 7 weeks of HFD, both saline- and OT-infused
rats exhibited a deterioration in the second GTT compared to the
first one (Figure 8A; P,0.05). However, this deterioration was
significantly lower in the OT- than in the saline-infused group
(Figure 8A; P,0.05). In addition, while it was accompanied by
insulin oversecretion in saline-infused animals (Figure 8B;
P,0.05), this did not occur in OT-infused rats, suggesting that
OT might protect against HFD-induced glucose intolerance and
insulin resistance.
To confirm these results, we performed euglycemic-hyperinsu-
linemic clamps. We found that, compared to saline-infused rats,
i.c.v. OT-infused animals displayed significant increases in the
glucose infusion rate (GIR; Figure 8C; P,0.05), indicating the
presence of increased insulin sensitivity. Similar results were
obtained by infusing OT peripherally (Figure 8D; P,0.05). The
latter data showed in addition that the OT-induced increase in
insulin sensitivity was unrelated to the decrease in food intake, as it
was not observed in the PF control group.
The effects of OT on lipid metabolism in adipose tissue and
their main consequences on metabolic homeostasis are summa-
rized by Figure 9.
Discussion
As mentioned in the Introduction, recent data showed that
central OT infusion causes body weight loss in diet-induced obese
mice [6]. The present study aimed at unraveling the mechanisms
underlying such anti-obesity effects of OT. Our results first
extended those of the literature by showing that central OT
infusion decreased body weight gain in diet-induced obese rats
independently from changes in food intake. Central OT
administration also decreased plasma TG levels. These changes
were accompanied by increases in the epididymal adipose tissue
(eWAT) expression of Lpl and of enzymes involved in lipolysis and
fatty acid b-oxidation, without any alteration in lipid metabolism
in skeletal muscles or the liver. Although was not investigated in
the present study, it is possible that, in addition to its effects on
lipolysis and b-oxidation, OT could have modified adipogenesis.
Indeed, it has been shown that OT and carbetocin (a stable OT
analogue) negatively modulate adipogenesis, while promoting
osteogenesis in human multipotent adipose-derived stem
(hMADS) cells [8]. An important additional observation was that
upon central infusion, hypothalamic mRNA and plasma OT levels
increased, suggesting that OT induced its own synthesis and
release into the bloodstream. This raised the possibility that OT
might modulate lipid metabolism in adipose tissue by direct action.
This was tested and confirmed using in vitro differentiated 3T3-L1
adipocytes, isolated epididymal fat pads studied ex vivo, as well as in
vivo peripheral administration in lean or obese rats.
We next attempted to delineate the mechanisms by which OT
stimulated fatty acid b-oxidation in adipose tissue. Both in
centrally OT-infused rats, as well as in cultured differentiated
3T3L1 adipocytes, we observed OT-induced increases in eWAT
Scd1 mRNA expression. The importance of Scd1 in metabolic
homeostasis was previously evidenced in studies conducted with
Scd1-deficient mice. Although hyperphagic, these mice were
protected against obesity, exhibiting decreased expression of
lipogenic enzymes and increased expression of enzymes involved
in fatty acid b-oxidation in the liver. In addition, Scd1 deficiency
promoted reduced hepatic TG storage [25]. However, the
consequences of Scd1 deficiency are complex, as, in addition to
the anti-obesity effects just described, other data provide evidence
that Scd1 inhibition is detrimental to adipocyte function, leading
to unwanted side effects. Such side effects appear to result from
increases in the ratio of saturated versus monounsaturated fatty
acids in membrane phospholipids (PL) [26,27,28,29]. Of partic-
ular interest for our study, decreased membrane oleic acid PL was
observed in Scd1-deficient mice [28], Scd1 knockdown in human
adipocytes [29] and HeLa cells [27]. According to these results,
the OT-induced increase in Scd1 expression observed in our study
was expected to increase the production of oleic acid PL,
particularly when considering that lipid storage was unchanged
by OT infusion. Oleic acid is known to serve as a precursor of
NOPE, leading to the synthesis of OEA, a member of the
endocannabinoid-related family of lipids, which was previously
shown to reduce food intake [7]. Consistent with our observation
of elevated OT-induced Scd1 expression, we observed increases in
eWAT NOPE and OEA content. Interestingly, OEA has been
shown to stimulate lipolysis and fatty acid oxidation, effects
Figure 6. Peripheral OT effects in HFD fed rats. The measure-
ments were performed over a 14-day experimental period (weeks 5
through 7 of a high fat diet) in s.c. saline–infused controls (black circles,
filled bars), s.c. OT-infused rats (50 nmol/d; white diamonds, open bars),
and s.c. saline-infused PF controls (black triangles, hatched bars): (A)
Cumulative body weight gain; (B) cumulative food intake; (C) changes
in body composition between days 0 and 10 of treatment. (D) Plasma
OT levels; (E) NOPE and (F) OEA content in eWAT. Values are mean 6
SEM of 7 to 8 rats/group. *P,0.05, **P,0.01 compared to controls.
doi:10.1371/journal.pone.0025565.g006
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resulting from OEA activation of PPAR-alpha [23,24]. These
effects may be important during food deprivation, when both
plasma OT levels [30] and WAT OEA content [31] are reportedly
increased. In addition, most of the OT upregulated genes that
encoded enzymes involved in b-oxidation were PPAR-alpha target
genes [32], consistent with the hypothesis that OT enhances
adipose tissue PPAR-alpha activity. Supporting this notion, we
observed that peripheral OT administration promoted a signifi-
cant decrease in body weight gain and an increase in the
expression of genes involved in fatty acid oxidation in wild-type
(WT) mice, but had no effect in PPAR-alpha knockout animals. The
additional observation that OT enhanced Scd1 expression not only
in WT, but also in PPAR-alpha knockout mice suggested that the
OT effect on Scd1 was upstream PPAR-alpha activation. This is
consistent with the reported downregulation of the PPAR-alpha
pathway in the heart of Scd1-deficient mice [33], as well as with the
upregulation of Scd1 and the PPAR-alpha pathway in muscles
after endurance training [34].
Interestingly, while our results suggest that OT acts on adipose
tissue via OEA and PPAR-alpha, a very recent study shows that
peripheral OEA suppresses feeding via increasing the central
release of OT [35]. This increase was absent in PPAR-alpha KO
mice, and the pharmacological blockade of central OT receptors
was able to prevent the anorexigenic effects of OEA [35]. These
data, together with those of the present study, support the
existence of complex interrelationships between OT and OEA,
which would play an important role in the regulation of food
intake and lipid metabolism.
In addition to protecting rats from HFD-induced obesity, we
found that central OT infusion improved glucose tolerance and
significantly reduced insulin secretion during the glucose tolerance
test, indications of increased insulin sensitivity. Such improvement
in insulin sensitivity was confirmed by euglycemic-hyperinsulin-
emic clamps carried out in both centrally and peripherally OT-
infused rats. Regarding the mechanisms underlying such OT
effects, they remain to be unraveled. The fact that OEA
administration was reported to promote glucose intolerance
without altering insulin levels [36] suggests that the OT effects
on glucose tolerance are independent from OEA synthesis.
Altogether, these results are in keeping with those of a previous
study showing that OT-deficient mice exhibit glucose intolerance
and decreased insulin sensitivity [4].
In view of the present data, the question of the metabolic impact
of physiological OT increases, such as those occurring during
labor and lactation can be raised. Although speculative, some
hypothesis can be proposed and might deserve to be tested. During
pregnancy, central opioids transiently inhibit OT neurons to
prevent preterm labor [37]. This inhibits OT release in the
posterior pituitary and lowers plasma OT levels [37]. Knowing
that about 3–15% of women develop gestational diabetes mellitus
[38], characterized by insulin resistance and increased insulin
secretion, our results could suggest that inhibition of OT neurons
Figure 7. PPAR-alpha mediates peripheral OT effects. (A) Cumulative body weight gain after 3 days of s.c. saline or OT treatment in PPAR-
alpha KO and wild-type (WT) mice. (B) eWAT mRNA expression of PPAR-alpha target genes and Scd1 in PPAR-alpha KO and WT mice. Values are mean
6 SEM of 5 animals/group. *P,0.05 compared to controls.
doi:10.1371/journal.pone.0025565.g007
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would, at least partly, be responsible for this insulin resistant state.
Conversely, during suckling, OT is secreted to promote milk
ejection. Potentially, the elevation in OT levels during this period
could contribute to the increased Lpl activity observed in the
mammary gland [39].
Considering a potential use of OT as an anti-obesity agent, an
important issue to be addressed is that of potential side effects of
the treatment. As eluded to above, one of the main physiological
OT effects is to induce uterine contraction during labor, a
condition in which plasma OT levels increase by 7 folds [40]. One
of the potential side effects of an anti-obesity OT treatment would
therefore be to promote uterine contraction. However, during
labor, it was demonstrated that the OTR concentration in the
myometrium is increased by more than 150 times to increase the
sensitivity of the uterus to OT [41]. Importantly, it was
demonstrated that both the decline of progesterone resulting from
luteolysis and the increased endogenous oestrogen levels after
luteolysis are necessary for the induction of OTR mRNA during
parturition [42]. Taken together, these results suggest that in
normal conditions, in which oestrogen levels are normal, basal
uterine OTR levels will not allow OT to induce uterine
contraction.
In summary, our study confirms and extends the recent data
showing anti-obesity effects of central OT administration. It allows
concluding that these effects are independent from the anorexi-
genic action of OT and bear on fat mass loss. The mechanisms
involved comprise OEA production in adipose tissue, activation of
PPAR-alpha and resulting increased fatty acid b-oxidation. These
effects are exerted by direct action of OT on adipocytes. Upon
central OT infusion, this is due to the positive feedback effect of
the hormone on its own secretion, resulting in dose-dependent
increases in plasma OT levels. Similar results can be obtained by
peripheral OT administration. Whether infused centrally or
peripherally, chronic OT infusion also improves insulin sensitivity
Figure 8. Central and peripheral OT infusion protects against high fat diet-induced insulin resistance. I.c.v. saline- (black circles) or OT-
(1.6 nmol/d; white diamonds) infused rats received: glucose tolerance tests (1.5 g/kg) before (black triangles, dashed line; 3 weeks of HFD; n = 16 rats)
or after infusions (7 weeks of HFD; 14-day i.c.v. infusions; n = 6 for each treatment group): (A) delta glucose and (B) delta insulin; One-way ANOVA:
*P,0.05 compared to black triangles; {P,0.05 compared to black circles. (C–D) Euglycemic-hyperinsulinemic clamps performed at the end of 14-day
treatments: (C) Glucose infusion rate (GIR) of i.c.v. saline- (filled bars) or OT- (1.6 nmol/d; open bars) infused rats. Values are mean6 SEM of 6 to 7 rats/
group. *P,0.05 compared to controls. (D) GIR of s.c. saline–infused controls (filled bars), OT-infused rats (50 nmol/d; open bars), and saline-infused PF
controls (hatched bars). Values are mean 6 SEM of 6 to 7 rats/group. *P,0.05.
doi:10.1371/journal.pone.0025565.g008
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Figure 9. Summary of the metabolic effects of oxytocin. Upon chronic central (i.c.v.) or peripheral (s.c.) infusion into diet-induced obese rats,
oxytocin (OT) increases triglyceride (TG) uptake, lipolysis, and fatty acid b-oxidation in adipose tissue. OT activates stearoyl-Coenzyme A desaturase 1
(Scd1) to produce the endocannabinoid oleoylethanolamide (OEA), a known ligand of PPAR-alpha. The action of OT on fatty acid b-oxidation is thus
exerted by direct activation of PPAR-alpha target genes via the production of OEA. Red arrows indicate the direction (up or down) of regulation.
Abbreviations: ACOX (acyl-CoA oxidase 1), ACC (acetyl-coenzyme A carboxylase alpha), ATGL (patatin-like phospholipase domain containing 2), DG
(diglycerides), DGAT1 (diacylglycerol O-acyltransferase homolog 1), FA (fatty acid), FAS (fatty acid synthase), GLUT4 (glucose transporter-4), HD (enoyl-
CoA hydratase/3-hydroxyacyl-CoA dehydrogenase), HSL (hormone-sensitive lipase), LPL (lipoprotein lipase), MCAD (medium chain acyl-CoA
dehydrogenase), MG (monoglycerides), MGL (monoglyceride lipase), NOPE (N-oleoyl-phosphatidylethanolamine), OA (oleic acid), SA (stearic acid),
PPAR-a (peroxisome proliferator-activator receptor-alpha).
doi:10.1371/journal.pone.0025565.g009
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of diet-induced obese rats. Altogether, these results suggest that
activation of the OT receptor pathway by infusion of OT, OT
analogs, or OT agonists represents a promising approach for
treating obesity and type 2 diabetes.
Supporting Information
Figure S1 Central OT infusion does not modify lipid
metabolism in skeletal muscle and in the liver. mRNA
expression of enzymes related to lipid metabolism in: (A)
quadriceps and (B) the liver of saline–infused controls (filled bars)
and i.c.v. oxytocin-infused rats (1.6 nmol/d; open bars). Values
are mean 6 SEM of 6 to 7 animals/group. Intergroup differences:
NS.
(TIF)
Figure S2 Central OT infusion does not modify OT and
OTR mRNA expression in eWAT. The following parameters
were measured at the end of 14-day treatments with two doses of
i.c.v. OT infusion: (A) Oxytocin (Oxt) and (B) Oxytocin receptor
(OxtR) expression in rat eWAT of saline–infused controls (filled
bars) and OT-infused rats (1.6 nmol/d, open bars). Values are
mean 6 SEM of 6 to 7 rats/group. (C) Oxytocin (Oxt) and (D)
Oxytocin receptor (OxtR) expression in rat eWAT of saline–infused
controls (filled bars), OT-infused rats (16 nmol/d, open bars) and
pair-fed (PF) controls (hatched bars). Values are mean6 SEM of 6
to 7 rats/group.
(TIF)
Figure S3 OEA affects lipid metabolism in cultured
adipocytes. (A) PPAR-alpha and PPAR-alpha target gene
expression in differentiated 3T3-L1 adipocytes (24 h vehicle or
0.2 mM OEA). Values are mean 6 SEM of three independent
experiments. *P,0.05 compared to controls.
(TIF)
Figure S4 Effects of peripheral OT infusion on lipid
metabolism-related parameters in eWAT. The following
analyses were performed on eWAT of s.c. saline–infused controls
(filled bars), s.c. OT-infused rats (50 nmol/d; open bars), and s.c.
saline-infused PF controls (hatched bars): (A) TG; (B) FFA and (C)
glycerol content. Values are mean 6 SEM of 7 to 8 rats/group.
*P,0.05, **P,0.01 compared to controls.
(TIF)
Table S1 Primer sequences used for qPCR.
(DOC)
Table S2 Effects of i.c.v. oxytocin (1.6 nmol/d) infusion
on food intake, meal number, meal size, meal duration,
feeding rate, intermeal interval (IMI) and satiety ratio.
Values are mean 6 SEM of 6 animals per group. P=NS for all
comparisons.
(DOC)
Table S3 Effects of i.c.v. oxytocin (16 nmol/d) infusion
on food intake, meal number, meal size, meal duration,
feeding rate, intermeal interval (IMI) and satiety ratio.
Values are mean 6 SEM of 7 animals per group. * P,0.05, **
P,0.01 versus saline-infused controls. P =NS for all other
comparisons.
(DOC)
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